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mpact on Prevalence of Impaired Fasting
lucose, Coronary Heart Disease Risk Factors, and
oronary Heart Disease in a Community-Based Medical Practice
un H. Kim, MD,* Lubna Chunawala, MS,† Randolph Linde, MD,† Gerald M. Reaven, MD*
tanford and Palo Alto, California
OBJECTIVES The goals of this study were to assess the effect of the 2003 American Diabetes Association
definition of impaired fasting glucose (IFG) on prevalence of IFG, coronary heart disease
(CHD) risk factors, and CHD compared with the 1997 IFG definition.
BACKGROUND Although IFG is viewed as increasing CHD risk, this association is unclear and has not been
well studied after changing the IFG criterion, especially in a clinical practice setting.
METHODS This was a cross-sectional evaluation of 8,295 members (3,763 men and 4,532 women) of a
community medical center who were between the ages of 30 and 69 years, without a history
of diabetes mellitus, and who had available measurements of fasting plasma glucose and lipid
concentrations within the past 2 years. The prevalence of IFG, CHD risk factors, and CHD
with the 1997 and 2003 IFG definition was compared.
RESULTS The prevalence of IFG increased from 8% to 35% with the 2003 criterion. Individuals with
glucose of 100 to 109 mg/dl had lower prevalence of most CHD risk factors (hypertension,
triglyceride 150 mg/dl, high-density lipoprotein cholesterol 40 mg/dl, meeting 2
components of the metabolic syndrome criteria, CHD risk 10% by Framingham score)
compared with individuals with glucose 110 to 125 mg/dl. Individuals identified with the
2003 IFG definition did not have an increase in known CHD when adjusted for covariates
(odds ratio 1.4 [95% confidence interval (CI) 0.7 to 2.3] vs. 3.2 [95% CI 1.8 to 5.9]).
CONCLUSIONS One-third of the population has IFG with the 2003 definition, yet many of these individuals
do not have increased prevalence of CHD risk factors or CHD. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.04348:293–7) © 2006 by the American College of Cardiology Foundation
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In 2003, the American Diabetes Association (ADA) low-
red the fasting plasma glucose concentration range for
iagnosing impaired fasting glucose (IFG) from 110 to 125
g/dl to 100 to 125 mg/dl in an effort to better identify
ndividuals at future diabetes risk (1). This change was also
ntended to improve selection of individuals at risk for
oronary heart disease (CHD) (2). Impaired fasting glucose,
owever, might not be an independent predictor of CHD.
revious studies that have reported an independent role
3,4) might have lacked adjustment for established CHD
isk factors in the analysis compared with those that did not
5,6). Even so, two major organizations recently incorpo-
ated the wider definition of IFG into the diagnostic criteria
f the metabolic syndrome to better identify individuals at
ncreased CHD risk (7,8).
Critics, however, have been concerned about the public
ealth implications of this change (9–12), which might
From the *Department of Medicine, Stanford University School of Medicine,
tanford, California; and the †Department of Medicine, Palo Alto Medical Foun-
ation, Palo Alto, California. Dr. Kim is supported by a National Research Service
ward (AA-014470-01) from the National Institutes of Health, Bethesda, Maryland.t
Manuscript received November 23, 2005; revised manuscript received March 6,
006, accepted March 16, 2006.reatly increase the number of individuals labeled with IFG
ithout a clear understanding of the benefits associated with
his diagnosis. The present cross-sectional study was initi-
ted to compare the prevalence of IFG, CHD risk factors,
nd CHD with the 1997 and 2003 IFG definition in a large
ommunity-based medical practice.
ETHODS
he study population consisted of 8,295 members (3,763
en and 4,532 women) of the Palo Alto Medical Founda-
ion, a community medical center located in Palo Alto,
alifornia. Individuals were selected from the Medical
oundation database if they were between 30 and 69 years
f age, without a history of diabetes mellitus (13), and had
vailable measurements of fasting plasma glucose and lipid
oncentrations within the past 2 years. Individual ethnicities
ould not be obtained, but the Palo Alto community
omprises 75.8% whites, 17.2% Asians, 4.6% Hispanics,
nd 2% blacks on the basis of the 2000 census (14). The
nstitutional Review Board of Palo Alto Medical Founda-
ion approved this study.
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Prevalence of IFG, CHD Risk Factors, and CHD July 18, 2006:293–7Laboratory and clinical information was retrieved from
he Medical Foundation database and included demograph-
cs (age, gender), anthropometric measurements (height,
eight, and blood pressure), medication profile, current
moking status, and diagnoses of hypertension and CHD.
ody mass index (BMI) was calculated as weight in kilo-
rams divided by the square of height in meters (kg/m2). A
erson was considered to have hypertension if they had been
reviously diagnosed with hypertension, took blood pressure
edications, or had systolic blood pressure 130 mm Hg
nd diastolic blood pressure 85 mm Hg. An individual
as regarded as having CHD if this diagnosis was listed in
heir medical profile.
The CHD risk factors evaluated included overweight/
besity status (BMI 25 kg/m2), presence of hypertension,
otal cholesterol 200 mg/dl, low-density lipoprotein-
holesterol (LDL-C) 100 mg/dl, high-density lipoprotein-
holesterol (HDL-C) 40 mg/dl, and 10-year CHD risk of
10% by Framingham point scores (15). Because insulin
esistance is appreciated as an emerging risk factor for CHD
16), we thought it useful to assess the impact of the two
efinitions of IFG on surrogate estimates of insulin resis-
ance. For this purpose we evaluated the effect of the 1997
nd 2003 classification of IFG on plasma triglyceride and
DL-C concentrations (17), the plasma triglyceride/
DL-C concentration ratio (18), and the presence of the
etabolic syndrome criteria as proposed by the National
holesterol Education Program (7,15). The components of
he metabolic syndrome are as follows: fasting plasma
lucose 100 mg/dl, triglycerides 150 mg/dl (1.7 mmol/
), HDL-C 40 mg/dl (1.036 mmol/l) in men and 50
g/dl (1.295 mmol/l) in women, blood pressure 130/85
mHg, and waist circumference102 cm in men and88
m in women. Because waist circumference was not avail-
ble, BMI 29 kg/m2 for men and 25 kg/m2 for women
ere substituted. These BMI values were chosen because they
rovide similar prevalence of the metabolic syndrome in the
hird National Health and Nutrition Examination Survey as
sing the waist circumference cut points (19).
All laboratory measurements were conducted by the
ills-Peninsula Health Services Laboratory in San Mateo,
alifornia. The LDL-C concentration was determined
ccording to Friedewald Formula (20). Approximately 1%
f the study population had a triglyceride level399 mg/dl,
Abbreviations and Acronyms
ADA  American Diabetes Association
BMI  body mass index
CHD  coronary heart disease
CI  confidence interval
HDL-C high-density lipoprotein-cholesterol
IFG  impaired fasting glucose
LDL-C  low-density lipoprotein-cholesterol
OR  odds ratiohere LDL-C could not be determined. cWe excluded 947 of the 9,242 individuals who met initial
ntry criteria for missing BMI (n  942) and hypertension
n  56) information. Individuals were classified according
o their fasting plasma glucose concentration as 100, 100
o 109, and 110 to 125 mg/dl. A general linear model was
sed to estimate the trend of variables across glucose
ategories with Cochran-Armitage test for trend used for
roportions. Pairwise comparisons between glucose catego-
ies were adjusted for multiple comparisons with Scheffé’s
ethod; the adjusted p values are reported. Logistic regres-
ion analysis was used to estimate the odds ratio (OR) and
5% confidence intervals (CIs) for having specified cardio-
ascular risk factors by glucose category. Fasting plasma
lucose concentration 100 mg/dl was set as the reference
roup. We adjusted for age, gender, BMI, and current
moking status in the model when testing for association
etween glucose categories and CHD. We also examined
otential interactions of the glucose categories with age,
ender, and BMI by using product terms. The p values
0.05 were considered significant. All analyses were con-
ucted with SAS version 9.1 (SAS Institute, Cary, North
arolina).
ESULTS
f 8,295 total individuals, 659 (8%) had a fasting glucose
evel of 110 to 125 mg/dl, 2,214 (27%) had a fasting glucose
evel of 100 to 109 mg/dl, and 5,422 (65%) had a fasting
lucose level 100 mg/dl. Employing the 2003 ADA
efinition of IFG, which includes glucose from 100 to
25mg/dl, more than one-third of the study population
35%) qualified for this diagnosis.
Table 1 describes the clinical and laboratory characteris-
ics of the individuals classified according to their fasting
lucose status. Individuals with plasma glucose concentra-
ion at or above 100 mg/dl were more likely to be male and
ore likely to smoke when compared with those with
lucose 100 mg/dl. With progressive increase in glucose
oncentration, individuals also tended to be older, heavier,
nd had higher blood pressure and heart rate. In addition,
ipid components showed increased triglycerides and de-
reased HDL-C, resulting in a rise in the triglyceride/
DL-C ratio from a mean of 2.2 in individuals with
lucose 100 mg/dl to 3.5 in those with glucose of 110 to
25 mg/dl. Although total cholesterol and LDL-C showed
linear association with glucose, levels in individuals with
lucose 100 to 109 mg/dl were not significantly different
rom individuals with glucose 110 to 125 mg/dl.
To provide additional insight into the effect of fasting
lasma glucose concentration on CHD risk, Table 2 shows
he frequency and OR for the occurrence of several relevant
ariables by glucose category. The prevalence of most
ariables was increased in the two groups with the higher
asting plasma glucose values. Because this was qualitatively
imilar in both women and men, we pooled the data for OR
alculations, with fasting plasma glucose concentration
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July 18, 2006:293–7 Prevalence of IFG, CHD Risk Factors, and CHD100 mg/dl set as 1. The OR for every variable but total
holesterol and LDL-C was highest in the group with a
asting plasma glucose concentration between 110 and 125
g/dl, and the confidence limits did not overlap with the
alues in subjects whose fasting plasma glucose is between
00 and 109 mg/dl.
Lastly, Table 3 reports the prevalence of established
HD according to fasting plasma glucose category. Men
ad a greater frequency of CHD than women, but gender
id not significantly modify the effect between glucose
ategory and CHD; therefore, the OR calculations were
ombined. The odds of having had a CHD event were
bout three-fold higher in individuals with fasting plasma
lucose of 100 to 109 mg/dl (OR 2.8, 95% CI 1.6 to 4.8)
nd more than eight-fold higher in individuals with fasting
lasma glucose of 110 to 125 mg/dl (OR 8.5, 95% CI 4.8 to
4.9) when compared with persons with fasting plasma
lucose 100 mg/dl. Risk for CHD was attenuated when
djusted for age, gender, BMI, and smoking status, with the
isk being no longer significant in persons with glucose of
00 to 109 mg/dl (OR 1.4, 95% CI 0.8 to 2.4) but
emaining significant in those with the older definition of
FG (OR 3.2, 95% CI 1.7 to 6.0). There was no significant
nteraction with age or BMI.
ISCUSSION
hanging the IFG criterion to include individuals with
lucose of 100 to 109 mg/dl increased the prevalence of IFG
rom 8% to 35% of the nondiabetic population seen in a
arge community-based health care facility. This magnitude
f increase in the occurrence of IFG is in keeping with
ecently published estimates from the National Health and
utrition Examination Survey 1999 to 2000 dataset, where
he prevalence of IFG nearly tripled in the population with
he revised criterion (9). In individuals 50 to 64 years of age,
able 1. Clinical and Laboratory Characteristics According To G
Fasting Plasma
<100 mg/dl
(n  5,422)
100–109 m
(n  2,2
asting plasma glucose (mg/dl) 89  6 103  3
ge (yrs) 45  10 49  1
ale (%) 39% 58%
urrent smoker (%) 6% 8%
MI (kg/m2) 26  5 28  5
lood pressure (mm Hg)
Systolic 118  14 123  1
Diastolic 75  10 78  9
eart rate (beats/min) 73  10 74  1
otal cholesterol (mg/dl) 192  35 198  3
DL-C (mg/dl) 109  31 115  3
DL-C (mg/dl) 61  18 56  1
riglycerides (mg/dl) 115  76 138  8
riglycerides/HDL-C ratio 2.2  2 2.9  2
ata are presented as mean  SD unless otherwise noted. *Pairwise comparison with
g/dl versus 110–125 mg/dl, c: 100–109 mg/dl versus 110–125 mg/dl.
BMI  body mass index; LDL-C  low-density lipoprotein cholesterol; HDL-his translated into an increase in the diagnosis of IFG from a.9% to 30.9%. The degree of change with the 2003 IFG
riterion is not confined to the U.S., with a prevalence of
2% and 38%, respectively, in Singapore (10) and Denmark
11). On the basis of these findings, it seems reasonable to
onclude that approximately one-third of the adult popula-
ion of developed nations would qualify for the diagnosis of
FG with the 2003 ADA criterion.
In addition to the large number of additional individ-
als identified, individuals with fasting plasma glucose of
00 to 109 mg/dl had a substantially lower prevalence of
HD risk factors and established CHD when compared
ith those with glucose of 110 to 125 mg/dl. They were
uch less likely to have hypertension and had lower
riglyceride and higher HDL-C concentrations. They
lso met fewer of the criteria for the metabolic syndrome
nd were less likely to have at least a 10-year 10% risk of
HD by Framingham scoring. Indeed, the only CHD
isk factor that did not decrease in magnitude in individ-
als with glucose of 100 to 109 mg/dl was the concen-
ration of LDL-C.
In support of this lower risk, individuals with glucose
evels of 100 to 109 mg/dl had lower odds of having
stablished CHD compared with individuals with glucose
f 110 to 125 mg/dl, with unadjusted ORs of 2.8 (95% CI
.6 to 4.8) and 8.5 (95% CI 4.8 to 14.9), respectively.
djusting for covariates attenuated the ORs to 1.4 (95% CI
.8 to 2.4) and 3.2 (95% CI 1.7 to 6.0), respectively,
ndicating that only the individuals with the 1997 definition
f IFG had a significantly greater prevalence of CHD.
herefore, although increased plasma glucose concentration
as associated with having more CHD risk factors, it was
ot an independent risk factor for having established CHD
n the additional individuals identified by the 2003 IFG
riterion. Conversely, our data show that fasting plasma
lucose level of 110 to 125 mg/dl was significantly associ-
se Category
cose
p Value
for
Trend
p Value
for Pairwise
Comparison*
110–125 mg/dl
(n  659)
115  4 — —
51  10 0.0001 a, b, c
58% 0.0001 a, b, c (NS)
9% 0.0001 a, b, c (NS)
30  6 0.0001 a, b, c
127  15 0.0001 a, b, c
79  9 0.0001 a, b, c
75  11 0.0001 a, b, c
197  37 0.0001 a, b (p  0.003), c (NS)
114  32 0.0001 a, b, c (NS)
53  16 0.0001 a, b, c (p  0.003)
159  133 0.0001 a, b, c
3.5  3 0.0001 a, b, c
.001 unless otherwise noted, a: glucose 100 mg/dl versus 100–109 mg/dl, b: 100
igh-density lipoprotein cholesterol.luco
Glu
g/dl
14)
0
4
1
5
0
6
8
p  0ted with having known CHD. Whether this is a true
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Prevalence of IFG, CHD Risk Factors, and CHD July 18, 2006:293–7ssociation also has been debated even before the institution
f the 2003 IFG criterion (5,6). Recently, examination of
he data from the Heart and Estrogen/progestin Replace-
ent Study supports our findings, showing a lack of
ssociation between the 2003 IFG definition and new CHD
vents in 2,763 postmenopausal women with established
HD, whereas there was increased risk in those fulfilling
he 1997 IFG criterion (21). Although the independent
Table 2. Prevalence of Coronary Heart Diseas
BMI 25 kg/m2
100
100–109
110–125
Hypertension
100
100–109
110–125
Total cholesterol 200 mg/dl
100
100–109
110–125
LDL-C 100 mg/dl
100
100–109
110–125
HDL-C 40 mg/dl
100
100–109
110–125
Triglycerides 150 mg/dl
100
100–109
110–125
Triglycerides/HDL-C 3
100
100–109
110–125
Metabolic syndrome criteria 2 (aside from glucose)
100
100–109
110–125
Framingham 10-yr risk 10%
100
100–109
110–125
Fasting glucose ranges are mg/dl.
CI  confidence interval; OR  odds ratio; other abbrev
able 3. Prevalence of Coronary Heart Disease According to Glu
o. of cases of coronary heart disease (%)
Women
Men
Combined
ombined unadjusted OR (95% CI)
ombined adjusted OR (95% CI), age, gender, BMI, smoking statusbbreviations as in Tables 1 and 2.ssociation of fasting plasma glucose concentration with
HD will continue to be debated, we have provided
ubstantial evidence that the prevalence of CHD and its risk
actors is less in individuals with fasting plasma glucose
oncentration of 100 to 109 mg/dl as compared with levels
f 110 to 125 mg/dl.
In conclusion, there are two important effects of widening
he fasting plasma glucose criterion for making a diagnosis of
k Factors According to Glucose Category
Prevalence Within
Glucose Category (%)
OR
(95% CI)
Women Men Combined Combined
44 67 53 1
66 78 73 2.4 (2.1–2.6)
81 82 82 3.9 (3.2–4.8)
15 26 19 1
28 39 34 2.2 (2.0–2.5)
48 51 50 4.2 (3.6–5.0)
39 40 40 1
50 43 46 1.3 (1.2–1.4)
52 39 44 1.2 (1.0–1.4)
54 69 60 1
68 69 69 1.5 (1.3–1.6)
69 63 65 1.3 (1.0–1.5)
3 17 8 1
5 18 12 1.5 (1.3–1.8)
9 23 17 2.3 (1.8–2.9)
14 31 21 1
25 36 31 1.7 (1.5–1.9)
36 45 41 2.6 (2.2–3.1)
12 38 22 1
22 42 33 1.7 (1.6–1.9)
36 49 44 2.7 (2.3–3.2)
24 28 26 1
44 39 41 2.0 (1.8–2.2)
65 53 58 3.9 (3.3–4.6)
0.2 13 5 1
0.3 23 14 2.8 (2.4–3.4)
2.9 33 20 4.6 (3.7–5.8)
s as in Table 1.
Category
Fasting Plasma Glucose
<100 mg/dl 100–109 mg/dl 110–125 mg/dl
5 (0.2) 1 (0.1) 4 (1.4)
20 (1.0) 27 (2.0) 21 (5.5)
25 (0.5) 28 (1.3) 25 (3.8)
1 2.8 (1.6–4.8) 8.5 (4.8–14.9)
1 1.4 (0.8–2.4) 3.2 (1.7–6.0)e Riscose
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July 18, 2006:293–7 Prevalence of IFG, CHD Risk Factors, and CHDFG in our community-based medical practice: 1) approxi-
ately one-third of the patient population served by a large
ommunity-based health care facility has IFG; and 2) the
revalence of CHD and its risk factors are attenuated with
he 2003 IFG definition compared with the 1997 definition.
n the basis of the data presented, it is difficult to suggest
hat the 2,214 individuals identified with the 2003 criterion
eserve the same medical attention and possible therapeutic
ntervention as the 658 patients with IFG by the 1997
efinition. Indeed, irrespective of the criterion for IFG used,
he effectiveness of initiating an intervention strategy to
ecrease the development of CHD has not been established.
n the absence of such information, it seems reasonable to
uestion the utility of the clinical information gained by
dentifying the four-times-as-many individuals that meet
he 2003 definition of IFG, who are clearly at less risk of
HD than persons identified with the 1997 criterion. If the
iagnosis of IFG is to have clinical utility in identifying
pparently healthy individuals at increased CHD risk, the
rst step might more usefully be the initiation of an
xperimental protocol to evaluate the clinical utility of
ntervention efforts in individuals meeting the original
riterion of IFG (e.g., persons at the greatest risk of CHD).
eprint requests and correspondence:Dr. Sun H. Kim, Stanford
niversity Medical Center, 300 Pasteur Drive, Room S025,
tanford, California 94305-5103. E-mail: sunhkim@stanford.edu.
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